Boston Scientific Corporation $BSX Shares Sold by Ameriprise Financial Inc.

Ameriprise Financial Inc. lowered its stake in Boston Scientific Corporation (NYSE:BSX) by 29.5% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,491,562 shares of the medical equipment provider’s stock after selling 2,295,397 shares during the quarter. Ameriprise Financial Inc. owned approximately 0.37% of Boston Scientific worth $536,381,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC lifted its stake in shares of Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after buying an additional 226 shares during the period. Campbell & CO Investment Adviser LLC acquired a new position in Boston Scientific in the second quarter valued at $249,000. Advisors Capital Management LLC lifted its position in Boston Scientific by 46.5% during the second quarter. Advisors Capital Management LLC now owns 6,446 shares of the medical equipment provider’s stock worth $692,000 after buying an additional 2,046 shares during the period. Foundations Investment Advisors LLC boosted its stake in Boston Scientific by 16.1% in the 2nd quarter. Foundations Investment Advisors LLC now owns 4,178 shares of the medical equipment provider’s stock worth $449,000 after buying an additional 579 shares during the last quarter. Finally, Empower Advisory Group LLC increased its stake in shares of Boston Scientific by 188.9% during the 2nd quarter. Empower Advisory Group LLC now owns 94,747 shares of the medical equipment provider’s stock valued at $10,177,000 after acquiring an additional 61,954 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Neutral Sentiment: Zacks published a recap explaining why Boston Scientific dipped more than the broader market, noting recent volatility around the company. Useful for context on short‑term market reaction. Article Title
• Negative Sentiment: Citigroup lowered its price target for Boston Scientific to $94.00 — a formal analyst downgrade that can weigh on sentiment and may lead some funds to reprice positions. Article Title
• Negative Sentiment: Levi & Korsinsky (reported via PR Newswire) and others say a filed class action alleges Boston Scientific executives misrepresented U.S. electrophysiology procedure volumes — this is the substantive allegation that could lead to discovery, potential damages or settlement risk. Investors should watch pleadings and any company response. Article Title
• Negative Sentiment: Multiple plaintiff law firms (Rosen, Pomerantz, Glancy Prongay Wolke, Robbins Geller, Faruqi, Gross, Bernstein Liebhard, etc.) have issued shareholder alerts and deadline reminders (lead‑plaintiff motions due May 4, 2026). The coordinated outreach increases the likelihood of consolidated litigation and underscores ongoing legal scrutiny. Article Title

Insider Activity at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the sale, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.50% of the company’s stock.

Boston Scientific Stock Performance

NYSE:BSX opened at $69.15 on Monday. The firm’s fifty day simple moving average is $82.47 and its 200 day simple moving average is $93.21. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. Boston Scientific Corporation has a twelve month low of $67.56 and a twelve month high of $109.50. The firm has a market capitalization of $102.61 billion, a price-to-earnings ratio of 35.64, a PEG ratio of 0.97 and a beta of 0.69.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The firm had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same period in the prior year, the firm earned $0.70 EPS. The firm’s quarterly revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on BSX shares. Weiss Ratings lowered shares of Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, February 4th. JPMorgan Chase & Co. dropped their price target on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Barclays cut their price target on shares of Boston Scientific from $136.00 to $124.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 3rd. Needham & Company LLC cut their target price on Boston Scientific from $121.00 to $97.00 and set a “buy” rating on the stock in a research report on Thursday, February 5th. Finally, Truist Financial reduced their target price on Boston Scientific from $120.00 to $95.00 and set a “buy” rating on the stock in a report on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $108.00.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.